Abstract:For a long time, pioneers in the field of cancer cell metabolism, such as Otto Warburg, have focused on the idea that tumor cells maintain high glycolytic rates even with adequate oxygen supply, in what is known as aerobic glycolysis or the Warburg effect. Recent studies have reported a more complex situation, where the tumor ecosystem plays a more critical role in cancer progression. Cancer cells display extraordinary plasticity in adapting to changes in their tumor microenvironment, developing strategies to survive and proliferate. The proliferation of cancer cells needs a high rate of energy and metabolic substrates for biosynthesis of biomolecules. These requirements are met by the metabolic reprogramming of cancer cells and others present in the tumor microenvironment, which is essential for tumor survival and spread. Metabolic reprogramming involves a complex interplay between oncogenes, tumor suppressors, growth factors and local factors in the tumor microenvironment. These factors can induce overexpression and increased activity of glycolytic isoenzymes and proteins in stromal and cancer cells which are different from those expressed in normal cells. The fructose-6-phosphate/fructose-1,6-bisphosphate cycle, catalyzed by 6-phosphofructo-1-kinase/fructose 1,6-bisphosphatase (PFK1/FBPase1) isoenzymes, plays a key role in controlling glycolytic rates. PFK1/FBpase1 activities are allosterically regulated by fructose-2,6-bisphosphate, the product of the enzymatic activity of the dual kinase/phosphatase family of enzymes: 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase (PFKFB1-4) and TP53-induced glycolysis and apoptosis regulator (TIGAR), which show increased expression in a significant number of tumor types. In this review, the function of these isoenzymes in the regulation of metabolism, as well as the regulatory factors modulating their expression and activity in the tumor ecosystem are discussed. Targeting these isoenzymes, either directly or by inhibiting their activating factors, could be a promising approach for treating cancers.

Non-dietary Fructose Metabolism Contributes to the Warburg effect in Cancers

Fructose Metabolism Contributes to the Warburg effect

Fructose fuels tumor growth through the polyol pathway and GLUT 8 transporter

Fructose contributes to the Warburg effect for cancer growth

Fructose-induced metabolic reprogramming of cancer cells

AKR1B1 -dependent fructose metabolism enhances malignancy of cancer cells

Dietary fructose enhances tumour growth indirectly via interorgan lipid transfer

Fructose metabolism in tumor endothelial cells promotes angiogenesis by activating AMPK signaling and mitochondrial respiration.

Fructose promotes angiogenesis by improving vascular endothelial cell function and upregulating VEGF expression in cancer cells

Exploring fructose metabolism as a potential therapeutic approach for pancreatic cancer

Data from Fructose-Induced Mtorc1 Activation Promotes Pancreatic Cancer Progression Through Inhibition of Autophagy

Dietary Fructose-Mediated Adipocyte Metabolism Drives Antitumor CD8+ T Cell Responses.

GLUT5-mediated fructose utilization drives lung cancer growth by stimulating fatty acid synthesis and AMPK/mTORC1 signaling

Dietary fructose improves intestinal cell survival and nutrient absorption

Fructose 2,6-Bisphosphate in Cancer Cell Metabolism

Enhanced Fructose Utilization Mediated by SLC2A5 Is a Unique Metabolic Feature of Acute Myeloid Leukemia with Therapeutic Potential

Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver Metastasis.

The Warburg Effect Revisited through Blood and Electron Flow

Glucose Metabolism in Cancer: The Warburg Effect and Beyond

The Warburg Effect: How Does it Benefit Cancer Cells?

Fructose sweetens antitumor responses